Experimental lung cancer drug trial halted early

NCT ID NCT05765734

Terminated Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This early-stage study tested an experimental drug called TAS3351 in 18 people with advanced non-small cell lung cancer that had a specific genetic change (EGFR C797S mutation). The goal was to see if the drug was safe and could shrink tumors. The study was stopped early, so results are limited and the drug's effectiveness is not clear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Institut Gustave Roussy

Villejuif, Val De Marne, 94805, France
Leiden University Medical Center (LUMC)

Leiden, 2333ZA, Netherlands
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
Next Oncology - Virginia

Fairfax, Virginia, 22031, United States
Shizuoka Cancer Center

Sunto-gun, Shizuoka, 411-8777, Japan
Tennessee Oncology

Nashville, Tennessee, 37203, United States
Universitaetsklinikum Koeln

Cologne, North Rhine-Westphalia, 50937, Germany
University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER